Abstract：
:Up to one in four patients with nasopharyngeal carcinoma present with non-metastatic stage IV disease (i.e. T4 or N3). Distinct failure patterns exist, despite the routine adoption of contemporary treatment modalities such as intensity modulated radiotherapy and systemic chemotherapy. Concurrent chemoradiotherapy (CCRT) followed by adjuvant chemotherapy or induction chemotherapy followed by CCRT are commonly employed in this setting, with the latter emerging as the preferred option. Additionally, emerging radiation technologies like proton therapy has become available offering new opportunities for prevention of radiation-induced side effects. This article reviews not only the current treatment strategies, but also discusses novel ways to tackle this challenging disease with respect to the patterns of failure.
journal_name
Cancer Treat Revjournal_title
Cancer treatment reviewsauthors
Ng WT,Corry J,Langendijk JA,Lee AWM,Mäkitie A,Mendenhall WM,Rinaldo A,Rodrigo JP,Saba NF,Smee R,Strojan P,Suárez C,Vermorken JB,Ferlito Adoi
10.1016/j.ctrv.2020.101995subject
Has Abstractpub_date
2020-04-01 00:00:00pages
101995eissn
0305-7372issn
1532-1967pii
S0305-7372(20)30033-5journal_volume
85pub_type
杂志文章,评审abstract：:The HER2 oncogene encodes a transmembrane protein partially homologous to epidermal growth factor receptor. This oncogene has been studied mainly in breast cancer where it has prognostic, predictive and therapeutic target value. The expression of HER2 in epithelial ovarian cancer has been less studied. HER2 expression...
journal_title：Cancer treatment reviews
pub_type： 杂志文章,评审
doi：10.1016/j.ctrv.2006.01.001
更新日期：2006-05-01 00:00:00
abstract：:Despite recent progress in the diagnostic and therapeutic approaches to the management of women with breast cancer, at least one third of these women will ultimately die from their disease. This resulted in a new focus on breast cancer prevention, especially for the woman designed as "high-risk". The continuing challe...
journal_title：Cancer treatment reviews
pub_type： 杂志文章,评审
doi：10.1016/s0305-7372(02)00107-x
更新日期：2003-04-01 00:00:00
abstract：:Glioblastomas are intrinsic brain tumors thought to originate from neuroglial stem or progenitor cells. More than 90% of glioblastomas are isocitrate dehydrogenase (IDH)-wildtype tumors. Incidence increases with age, males are more often affected. Beyond rare instances of genetic predisposition and irradiation exposur...
journal_title：Cancer treatment reviews
pub_type： 杂志文章,评审
doi：10.1016/j.ctrv.2019.101896
更新日期：2019-11-01 00:00:00
abstract：:The prognosis for patients with relapsed/progressive non-small cell lung cancer (NSCLC) remains poor. For first-line therapy, a number of platinum-based regimens are standard; second-line therapies include single-agent docetaxel, pemetrexed, and erlotinib. Treatment options for patients whose tumors have failed to res...
journal_title：Cancer treatment reviews
pub_type： 杂志文章,评审
doi：10.1016/j.ctrv.2012.05.003
更新日期：2013-05-01 00:00:00
abstract：:Antiangiogenic agents (AAs) have reported grater efficacy compared to interferon. Despite these advances, radiological complete response to therapy is rare. We meta-analyzed the incidence of complete response in patients treated with AAs and in controls in main randomized clinical trials for first-line therapy in meta...
journal_title：Cancer treatment reviews
pub_type： 杂志文章,meta分析,评审
doi：10.1016/j.ctrv.2013.09.003
更新日期：2014-03-01 00:00:00
abstract：:Pancreatic cancer is a disease with a high mortality rate and short survival, as a result of the high incidence of metastatic disease at diagnosis, the fulminant clinical course and the lack of successful therapeutic strategies. The administration of chemotherapeutic agents for the treatment of advanced disease has fa...
journal_title：Cancer treatment reviews
pub_type： 杂志文章,评审
doi：10.1016/j.ctrv.2009.02.005
更新日期：2009-08-01 00:00:00
abstract：:Infertility is a common and distressing late-effect of cancer treatment. Whist sperm banking for post-pubertal males and embryo freezing for women (who are in a stable relationship at the time of treatment) are highly successful fertility preservation strategies, for females without a partner (including young and pre-...
journal_title：Cancer treatment reviews
pub_type： 杂志文章,评审
doi：10.1016/j.ctrv.2007.02.001
更新日期：2007-11-01 00:00:00
abstract：:There has been much progress in the understanding of the relationship between the immune system and colorectal cancer. This has led to the use of immunomodulatory therapy in the adjuvant and palliative treatment of the condition. Although attempts at the use of non-specific immunomodulation with agents such as levamis...
journal_title：Cancer treatment reviews
pub_type： 杂志文章,评审
doi：10.1053/ctrv.1999.0160
更新日期：2000-06-01 00:00:00
abstract：:Tissue hypoxia occurs where there is an imbalance between oxygen supply and consumption. Hypoxia occurs in solid tumours as a result of an inadequate supply of oxygen, due to exponential cellular proliferation and an inefficient vascular supply. It is an adverse prognostic indicator in cancer as it is associated with ...
journal_title：Cancer treatment reviews
pub_type： 杂志文章,评审
doi：10.1016/s0305-7372(03)00003-3
更新日期：2003-08-01 00:00:00
abstract：:Fulvestrant is a selective estrogen receptor downregulator, behaving as a complete antagonist. It was initially approved, at a dose of 250 mg, to treat hormone dependant breast cancer in second line setting. However, a series of pharmacological and pre-clinical studies have suggested that a higher dose of 500 mg may b...
journal_title：Cancer treatment reviews
pub_type： 杂志文章,评审
doi：10.1016/j.ctrv.2012.06.003
更新日期：2013-04-01 00:00:00
abstract：:Acute myeloid leukemia (AML) presents therapeutic challenges in older adults because of high-risk leukemia biology conferring chemoresistance, and poor functional status resulting in increased therapy-related toxicities. Recent FDA approval of 8 new drugs for AML has increased therapeutic armamentarium and also provid...
journal_title：Cancer treatment reviews
pub_type： 杂志文章,评审
doi：10.1016/j.ctrv.2019.04.001
更新日期：2019-05-01 00:00:00
abstract：:Radiotherapy is an indispensable unit of multidisciplinary treatment of breast cancer. Although the application of modern techniques has led to a significantly reduction in radiation-induced heart disease, it is still recognized as the leading causes of morbidity and mortality among breast cancer survivors. With the g...
journal_title：Cancer treatment reviews
pub_type： 杂志文章,评审
doi：10.1016/j.ctrv.2018.03.008
更新日期：2018-07-01 00:00:00
abstract：:Metastatic colorectal cancer (CRC) is most frequently seen in the liver. Resection of metastases remains the treatment of choice; however, the majority of patients are ineligible for surgery due to unfavorable location, size, or number of metastases; insufficient liver reserve; or extrahepatic disease. The activity of...
journal_title：Cancer treatment reviews
pub_type： 杂志文章,评审
doi：10.1016/j.ctrv.2008.01.004
更新日期：2008-06-01 00:00:00
abstract：:Paclitaxel, a novel antitumour agent, is active clinically against advanced ovarian and breast cancer and under investigation for various other cancers. One of the problems associated with the intravenous administration of paclitaxel is its low solubility in water. The current pharmaceutical formulation consists of a ...
journal_title：Cancer treatment reviews
pub_type： 杂志文章,评审
doi：10.1016/s0305-7372(97)90022-0
更新日期：1997-03-01 00:00:00
abstract：:Metastatic breast cancer is ultimately an incurable disease, although recent data have shown that its incidence is decreasing and that patients with metastatic breast cancer live longer. This improvement in survival seems to be linked with the introduction of new therapeutic agents, novel combinations of existing ther...
journal_title：Cancer treatment reviews
pub_type： 杂志文章,评审
doi：10.1016/j.ctrv.2009.10.001
更新日期：2010-02-01 00:00:00
abstract：:Neoadjuvant chemotherapy (NAC) for breast cancer is evolving and subsequent adjuvant systemic treatment is mainly based on the presence of the Estrogen (ER) receptor, Progesterone (PR) receptor and Human Epidermal growth factor Receptor 2 (HER2) status on the core needle biopsy prior to treatment. It is not well known...
journal_title：Cancer treatment reviews
pub_type： 杂志文章,评审
doi：10.1016/j.ctrv.2010.11.006
更新日期：2011-10-01 00:00:00
abstract：:In a clinical phase II study 151 patients with refractory malignant diseases were treated with ifosfamide (60 mg/kg/day i.v. days 1-5, q 21-28 days). Altogether, 490 courses of treatment were given, 92 with conventional prophylactic measures (continuous infusion of 3-4 litre physiological saline plus alkalinization of...
journal_title：Cancer treatment reviews
pub_type： 杂志文章
doi：10.1016/s0305-7372(83)80013-9
更新日期：1983-09-01 00:00:00
abstract：:Patients with advanced cancer often develop bone metastases that lead to significant skeletal morbidity and substantially reduced functionality and autonomy [Coleman RE, Rubens RD. Bone metastases. In: Clinical Oncology, 2nd edn. New York: Churchill Livingstone. 2004, p. 1091-128]. As current methods of diagnosing bon...
journal_title：Cancer treatment reviews
pub_type： 杂志文章,评审
doi：10.1016/s0305-7372(06)80001-0
更新日期：2006-01-01 00:00:00
abstract：:Due to differences in anatomy, primary rectal and colon cancer require different staging procedures, different neo-adjuvant treatment and different surgical approaches. For example, neoadjuvant radiotherapy or chemoradiotherapy is administered solely for rectal cancer. Neoadjuvant therapy and total mesorectal excision...
journal_title：Cancer treatment reviews
pub_type： 杂志文章,评审
doi：10.1016/j.ctrv.2015.06.007
更新日期：2015-09-01 00:00:00
abstract：:When focusing on heart disease, most available studies split the two different parts of the adjuvant treatment, i.e., systemic therapies and radiation therapy, making it difficult to implement efficient strategies for preventing treatment-induced cardiac toxicity. This paper reviews the current understanding of treatm...
journal_title：Cancer treatment reviews
pub_type： 杂志文章,评审
doi：10.1016/j.ctrv.2010.08.007
更新日期：2011-06-01 00:00:00
abstract：:Checkpoint blockades turn on a new paradigm shift in immunotherapy for cancer. Remarkable clinical efficacy, durable response and low toxicity of programmed death 1 (PD-1)/programmed death ligand-1 (PD-L1) checkpoint blockades have been observed in various malignancies. However, a lot of cancer patients failed to resp...
journal_title：Cancer treatment reviews
pub_type： 杂志文章,评审
doi：10.1016/j.ctrv.2015.11.001
更新日期：2015-12-01 00:00:00
abstract：:Triple-negative breast cancer (TNBC) accounts for ∼10-20% of breast cancers and is associated with relatively poor prognosis, earlier disease recurrence and higher number of visceral metastases. Despite an increasing understanding of the molecular heterogeneity of TNBC, clinical trials of targeted agents have thus far...
journal_title：Cancer treatment reviews
pub_type： 杂志文章,评审
doi：10.1016/j.ctrv.2016.09.004
更新日期：2016-11-01 00:00:00
abstract：:The interactions of cisplatin with other anti-cancer agents on the DNA level have been studied extensively in pre-clinical experiments. In general, combination of cisplatin with an antimetabolite, taxane, or topoisomerase inhibitor, can result in a modulation of platinum pharmacology on the DNA, for example, enhanced ...
journal_title：Cancer treatment reviews
pub_type： 杂志文章,评审
doi：10.1016/s0305-7372(02)00093-2
更新日期：2002-12-01 00:00:00
abstract：:Chemokines are proteins which induce chemotaxis, promote differentiation of immune cells, and cause tissue extravasation. Given these properties, their role in anti-tumor immune response in the cancer environment is of great interest. Although immunotherapy has shown clinical benefit for some cancer patients, other pa...
journal_title：Cancer treatment reviews
pub_type： 杂志文章,评审
doi：10.1016/j.ctrv.2017.11.007
更新日期：2018-02-01 00:00:00
abstract：:The term Unfit refers to older cancer patients not amenable with standard treatment and needing therefore a modified or attenuated treatment or also not deserving an active therapeutic approach. To determine whether an old patient is Unfit a Multidimensional Geriatric Evaluation is needed, but to spare time, shortened...
journal_title：Cancer treatment reviews
pub_type： 杂志文章
doi：10.1016/j.ctrv.2009.04.006
更新日期：2009-10-01 00:00:00
abstract：:Prostate cancer is the most common cancer in men. Overall survival is considered the best endpoint for clinical trials, but it is difficult to use in phase-2 studies. Although the reduction of PSA after cytotoxic chemotherapy has been identified as a valid surrogate for overall survival, it has not proven reliable for...
journal_title：Cancer treatment reviews
pub_type： 杂志文章,评审
doi：10.1016/j.ctrv.2012.03.008
更新日期：2012-12-01 00:00:00
abstract：BACKGROUND:Patients who are diagnosed with cancer want advice on how they may alter their diet or which diet supplements they should take to augment chemotherapy. METHODS:We conducted a review of the literature mostly from the last 15 years on the interaction between dietary constituents and antineoplastic therapy in ...
journal_title：Cancer treatment reviews
pub_type： 杂志文章,评审
doi：10.1016/j.ctrv.2006.12.004
更新日期：2007-05-01 00:00:00
abstract：:Glioblastoma is the most malignant and frequent primary brain tumour in adults. Current treatment remains insufficient as these tumours display a diffuse infiltrative growth pattern and tend to recur despite extensive debulking surgery followed by radio- and chemotherapy. The alkylating agents carmustine (1,3-bis-(2-c...
journal_title：Cancer treatment reviews
pub_type： 杂志文章,评审
doi：10.1016/j.ctrv.2008.03.125
更新日期：2008-10-01 00:00:00
abstract：:From a theoretical viewpoint, intraperitoneal therapy (IP) in patients with ovarian cancer, a malignancy which remains mainly confined to the peritoneal cavity, is logical. Over the past decades this approach has evolved into a therapeutic strategy for a selected group of patients. Data available at present suggest a ...
journal_title：Cancer treatment reviews
pub_type： 杂志文章
doi：10.1053/ctrv.1999.0152
更新日期：2000-04-01 00:00:00
abstract：:Historically, the median overall survival for patients with stage IV melanoma was less than 1 year and the 5-year survival rate was ∼10%. Recent advances in therapy have raised 5-year survival expectations to ∼20%. Notably, a subset of melanoma patients who receive immunotherapy with high-dose interleukin-2, and now i...
journal_title：Cancer treatment reviews
pub_type： 杂志文章,评审
doi：10.1016/j.ctrv.2014.06.012
更新日期：2014-10-01 00:00:00
